Detection and Quantification of Fluconazole Within Candida glabrata Biofilms


Candida infections are often associated with biofilms and consequent high resistance to most common drugs (e.g. azoles). These resistance mechanisms are not only associated with the biofilm yeast physiology, but also with the presence of a diffusional barrier imposed by the biofilm matrix; however, the real biochemical role of the biofilm components remains very unclear. So, in order to further clarify this issue, we intend to determine, for the first time, fluconazole in biofilms within both supernatants and matrices. Candida biofilms were formed in the presence of fluconazole, and it was recovered from both supernatant and matrix cell-free fractions. Then, high-pressure liquid chromatography was used to identify and quantify the amount of drug that was present in the two fractions. Moreover, this study also showed that the presence of fluconazole in both fractions indicated that the drug administrated did not completely reach the cells, so this phenomena can easily be associated with lower biofilm susceptibility, since the drug administered did not completely reach the cells.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2


  1. 1.

    Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009;52(3):197–205.

    Article  PubMed  Google Scholar 

  2. 2.

    Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288–305.

    Article  CAS  PubMed  Google Scholar 

  3. 3.

    Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–63.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. 4.

    Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R, Pallavicini FB, Viscoli C. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis. 2006;6:21.

    Article  PubMed Central  PubMed  Google Scholar 

  5. 5.

    Hagerty JA, Ortiz J, Reich D, Manzarbeitia C. Fungal infections in solid organ transplant patients. Surg Infect. 2003;4:263–71.

    Article  Google Scholar 

  6. 6.

    Kojic EM, Darouiche RO. Candida infections of medical devices. Clin Microbiol Rev. 2008;17:255–67.

    Article  Google Scholar 

  7. 7.

    Samaranayake LP, Fidel PL, Naglik JR, et al. Fungal infections associated with HIV infection. Oral Dis. 2005;8:151–60.

    Article  Google Scholar 

  8. 8.

    Rajendran R, Robertson DP, Hodge PJ, Lappin DF, Ramage G. Hydrolytic enzyme production is associated with Candida albicans biofilm formation from patients with type 1 diabetes. Mycopathologia. 2010;170:229–35.

    Article  CAS  PubMed  Google Scholar 

  9. 9.

    Kuhn DM, Ghannoum MA. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs. 2004;5:186–97.

    CAS  PubMed  Google Scholar 

  10. 10.

    Gerber F, Krummen M, Potgeter H, Roth A, Siffrin C, Spoendlin C. Practical aspects of fast reversed-phase high-performance liquid chromatography using 3 μm particle packed columns and monolithic columns in pharmaceutical development and production working under current good manufacturing practice. J Chromatogr A. 2004;1036(2):127–33.

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Sadasivudu P, Shastri N, Sadanandam M. Development and validation Of RP-Hplc and UV methods of analysis for fluconazole in pharmaceutical solid dosage forms. Int J Chem Tech Res. 2009;1(4):1131–6.

    CAS  Google Scholar 

  12. 12.

    Williams DW, Wilson MJ, Lewis MAO, Potts AJ. Identification of Candida species by PCR and restriction fragment length polymorphism analysis of intergenic spacer regions of ribosomal DNA. J Clin Microbiol. 1995;33:2476–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  13. 13.

    Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med Mycol. 2009;47:681–9.

    Article  CAS  PubMed  Google Scholar 

  14. 14.

    Rodrigues CF, Silva S, Henriques M. Candida glabrata: a review of its features and resistance. Eur J Clin Microbiol Infect Dis. 2014;33(5):673–88.

    Article  CAS  PubMed  Google Scholar 

  15. 15.

    Prażyńska M, Gospodarek E. In vitro effect of amphotericin B on Candida albicans, Candida glabrata and Candida parapsilosis biofilm formation. Mycopathologia. 2014;177(1-2):19–27.

    Article  PubMed  Google Scholar 

  16. 16.

    Nett JE. Future directions for anti-biofilm therapeutics targeting Candida. Expert Rev Anti Infect Ther. 2014;12(3):375–82.

    Article  CAS  PubMed  Google Scholar 

Download references


This work was supported by the Programa Operacional, Fatores de competitividade—COMPETE and by national funds through FCT—Fundação para a Ciência e a Tecnologia on the scope of the projects FCT PTDC/SAU-MIC/119069/2010, RECI/EBB-EBI/0179/2012, PEst-OE/EQB/LA0023/2013 and Célia F. Rodrigue’s SFRH/BD/93078/2013 PhD grant. The authors thank the Project “BioHealth—Biotechnology and Bioengineering approaches to improve health quality,” Ref. NORTE-07-0124-FEDER-000027, co-funded by the Programa Operacional Regional do Norte (ON.2—O Novo Norte), QREN, FEDER. We also would like to acknowledge Pfizer®, S.A., for the kindly donation of fluconazole.

Conflict of interest

The authors declare no competing financial interest.

Author information



Corresponding author

Correspondence to Mariana Henriques.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rodrigues, C.F., Silva, S., Azeredo, J. et al. Detection and Quantification of Fluconazole Within Candida glabrata Biofilms. Mycopathologia 179, 391–395 (2015).

Download citation


  • Candida
  • Biofilm matrix
  • Antifungal
  • Method
  • Resistance